Business Context and Reporting Period
Company: The Kroger Co.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Second quarter ended August 17, 2024 (12 weeks) and the first two quarters ended August 17, 2024 (28 weeks).
Business Overview: Kroger operates as a large accelerated filer in the omnichannel retail sector, focusing on grocery, fuel, and health and wellness. The company is currently navigating a proposed merger with Albertsons Companies, Inc., which requires significant regulatory divestitures and financing arrangements.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Sales | $33,912 | $33,853 | $79,181 | $79,018 |
| Operating Profit | $815 | $(479) | $2,109 | $991 |
| Net Earnings (Attributable to Kroger) | $466 | $(180) | $1,413 | $782 |
| Diluted EPS | $0.64 | $(0.25) | $1.93 | $1.07 |
| Operating Cash Flow (YTD) | $3,464 | $4,364 | ||
| Capital Investments (YTD) | $2,076 | $1,771 | ||
| Total Debt (End of Period) | $12,230 | $12,226 | ||
| Cash & Temporary Investments | $2,786 | $1,883 |
Note: Total Debt includes current and long-term portions of obligations under finance leases. YTD figures represent the two quarters ended August 17, 2024, and August 12, 2023.
Material Changes vs. Prior Period
- Profitability Turnaround: GAAP operating profit swung from a loss of $479 million in Q2 2023 to a profit of $815 million in Q2 2024. This improvement is largely attributable to the absence of the $1.4 billion opioid settlement charge recorded in Q2 2023.
- Adjusted Performance: On an adjusted basis (excluding merger costs, investment gains/losses, and opioid settlements), adjusted net earnings per diluted share decreased slightly by 3.1% to $0.93 in Q2 2024 compared to $0.96 in Q2 2023.
- Sales Growth: Total sales increased 0.2% year-over-year in Q2 2024. Identical sales excluding fuel grew 1.2%, driven by increased customer visits and Health and Wellness sales, partially offset by a reduction in items per basket.
- Fuel Sales Decline: Supermarket fuel sales decreased 8.0% in Q2 2024 due to lower average retail fuel prices and a 3.5% decline in gallons sold.
- Investment Losses: The company recorded a $121 million loss on investments in Q2 2024, primarily due to the termination of forward-starting interest rate swaps, compared to a $367 million gain in the prior year period.
Guidance, Outlook, and Risks
- Albertsons Merger: The proposed merger remains subject to regulatory approval. The company has entered into an amended divestiture plan with C&S Wholesale Grocers to sell 579 stores and certain banners to address antitrust concerns. The merger is currently facing litigation from the FTC and state attorneys general seeking injunctions.
- Financing: In August 2024 (subsequent to the reporting period), Kroger issued $10.5 billion in senior notes to fund the merger. The company terminated its $17.4 billion bridge loan facility commitment following these issuances.
- Divestitures: Kroger Specialty Pharmacy business is classified as "held for sale" with an expected sale price of approximately $485 million to CarelonRx, pending regulatory review.
- Capital Allocation: The company paused its share repurchase program in 2022 to prioritize de-leveraging for the merger. In Q2 2024, it repurchased $13 million of shares solely to offset dilution from employee stock plans. Dividends were increased to $0.29 per share.
- Risks: Key risks include the failure to consummate the Albertsons merger, potential regulatory divestitures exceeding current plans, labor negotiations, and the impact of inflation on operating costs.
Investor Verification Checklist
- Merger Status: Monitor the outcome of the FTC administrative proceeding and federal litigation regarding the Albertsons merger, as this dictates the use of the $10.5 billion in newly issued debt.
- Adjusted vs. GAAP Earnings: Verify the impact of non-recurring items (merger costs, investment losses) on core operational performance, as GAAP results are heavily influenced by these factors.
- Pharmacy Divestiture: Track the closing of the Kroger Specialty Pharmacy sale to CarelonRx and the associated tax adjustments.
- Debt Covenants: Confirm continued compliance with bank credit facility covenants, particularly given the significant increase in debt load from the August 2024 note issuances.
- Identical Sales Trends: Assess whether the 1.2% identical sales growth (excluding fuel) is sustainable given the reduction in items per basket and competitive pricing pressures.